Guselkumab, which was subcutaneously injected in the participating patients, was assessed for its efficacy and safety in the DISCOVER 1 and 2 trials compared to placebo. Janssen said The post Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials appeared first on Pharmaceutical Business review.

Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction The post Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria appeared first on Pharmaceutical Business review.

The Dialize trial has evaluated the efficacy and safety of Lokelma to treat hyperkalaemia, which is a serious condition indicated by elevated potassium levels in the blood. According The post AstraZeneca’s Lokelma shows significant effect in ESRD trial appeared first on Pharmaceutical Business review.

Previously known as COR-001, ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). The post Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab appeared first on Pharmaceutical Business review.

Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were The post Pfizer announces results from XELJANZ XR ORAL Shift study appeared first on Pharmaceutical Business review.